This is an NIH-funded, Phase III, multicenter, randomized, open-label, assessor-blinded, parallel two-arm, controlled clinical trial. 692 subjects with symptomatic proximal DVT that involves the iliac, common femoral, and/or femoral vein will be randomized in a 1:1 ratio to receive either adjunctive PCDT (with rt-PA) + standard DVT therapy or standard DVT therapy alone. Subjects will be enrolled over 2.5 years in 30-50 U.S. Clinical Centers, and followed for 24 months. The study will take 4.5 years to complete.
|Effective start/end date||4/1/09 → 3/31/16|
- Washington University in Saint Louis
Controlled Clinical Trials